Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -34.02% is 45% above its 5-year average of -61.58%, near the high end of its 5-year range (-135.23%–-25.31%).
11.79% below its 12-month average of -30.43%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -25.31%.
EBITDA MARGIN
-34.02%
EBITDA MARGIN AVG TTM
-30.43%
EBITDA MARGIN AVG 3Y
-38.66%
EBITDA MARGIN AVG 5Y
-61.58%
EBITDA MARGIN AVG 10Y
-64.11%
EBITDA MARGIN AVG 15Y
-85.33%
EBITDA MARGIN AVG 20Y
-85.33%
CURRENT VS TTM AVG
-11.79%
CURRENT VS 3Y AVG
+12.00%
CURRENT VS 5Y AVG
+44.76%
CURRENT VS 10Y AVG
+46.93%
CURRENT VS 15Y AVG
+60.13%
CURRENT VS 20Y AVG
+60.13%
Cytosorbents Corporation
Market Cap
$12.44M
EBITDA Margin
-34.02%
TTM Avg
-30.43%
3Y Avg
-38.66%
5Y Avg
-61.58%
Market Cap
$12.48M
EBITDA Margin
-1106.68%
TTM Avg
-120183.14%
3Y Avg
-60445.11%
5Y Avg
-60445.11%
Market Cap
$12.58M
EBITDA Margin
-6933.56%
TTM Avg
-9498.48%
3Y Avg
-11253.22%
5Y Avg
-11253.22%
Market Cap
$12.78M
EBITDA Margin
-5650.91%
TTM Avg
-5650.91%
3Y Avg
-12817.85%
5Y Avg
-12817.85%
Market Cap
$12.06M
EBITDA Margin
-16245.70%
TTM Avg
-13416.38%
3Y Avg
-13330.05%
5Y Avg
-20098.17%
Market Cap
$11.93M
EBITDA Margin
-19.85%
TTM Avg
-31.46%
3Y Avg
-46.77%
5Y Avg
-56.23%
Market Cap
$11.77M
EBITDA Margin
-1.94%
TTM Avg
-1.94%
3Y Avg
-10.48%
5Y Avg
-10.95%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cytosorbents Corporation (CTSO) | $12.44M | -34.02% | -30.43% | -38.66% | -61.58% |
| Dare Bioscience, Inc. (DARE)vs › | $12.48M | -1106.68% | -120183.14% | -60445.11% | -60445.11% |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.58M | -6933.56% | -9498.48% | -11253.22% | -11253.22% |
| Lantern Pharma Inc. (LTRN)vs › | $12.17M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.78M | -5650.91% | -5650.91% | -12817.85% | -12817.85% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.06M | -16245.70% | -13416.38% | -13330.05% | -20098.17% |
| Biofrontera Inc. (BFRI)vs › | $11.93M | -19.85% | -31.46% | -46.77% | -56.23% |
| Passage Bio, Inc. (PASG)vs › | $13.11M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $11.77M | -1.94% | -1.94% | -10.48% | -10.95% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | N/A | N/A | N/A | N/A |
Gross Margin
71.6%
EBITDA Margin
-34.0%
Operating Margin
-33.4%
Net Margin
-48.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -25.31% |
| 2026-03-31 | -30.10% |
| 2025-12-31 | -37.80% |
| 2025-09-30 | -25.95% |
| 2025-06-30 | -33.01% |
| 2025-03-31 | -39.90% |
| 2024-12-31 | -39.56% |
| 2024-09-30 | -46.07% |
| 2024-06-30 | -35.32% |
| 2024-03-31 | -46.87% |
| 2023-12-31 | -120.42% |
| 2023-09-30 | -88.83% |
| 2023-06-30 | -65.36% |
| 2023-03-31 | -80.78% |
| 2022-12-31 | -65.31% |
| 2022-09-30 | -135.23% |
| 2022-06-30 | -95.68% |
| 2022-03-31 | -94.76% |
| 2021-12-31 | -86.69% |
| 2021-09-30 | -58.07% |
| 2021-06-30 | -42.24% |
| 2021-03-31 | -26.58% |
| 2020-12-31 | -20.65% |
| 2020-09-30 | -17.61% |
| 2020-06-30 | -32.97% |
| 2020-03-31 | -28.17% |
| 2019-12-31 | -79.63% |
| 2019-09-30 | -95.83% |
| 2019-06-30 | -59.71% |
| 2019-03-31 | -90.60% |
| 2018-12-31 | -99.64% |
| 2018-09-30 | -50.40% |
| 2018-06-30 | -78.67% |
| 2018-03-31 | -68.68% |
| 2017-12-31 | -87.25% |
| 2017-09-30 | -60.62% |
| 2017-06-30 | -75.33% |
| 2017-03-31 | -57.54% |
| 2016-12-31 | -172.90% |
| 2016-09-30 | -98.18% |
| 2016-06-30 | -143.01% |
| 2016-03-31 | -128.84% |
| 2015-12-31 | -175.70% |
| 2015-09-30 | -197.57% |
| 2015-06-30 | -280.98% |
| 2015-03-31 | -318.23% |
| 2014-09-30 | -160.65% |
| 2014-06-30 | -203.83% |
| 2014-03-31 | -198.70% |
| 2013-12-31 | -314.24% |
| 2013-09-30 | -424.45% |
| 2013-06-30 | -1085.86% |
| 2013-03-31 | -799.47% |
| 2012-12-31 | 134.67% |
| 2012-09-30 | -97.51% |
| 2012-06-30 | -3024.31% |
| 2012-03-31 | -6252.84% |
| 2006-12-31 | 20244.10% |
| 2006-03-31 | -208.56% |
| 2005-12-31 | -127.91% |
| 2005-09-30 | 1279.82% |
